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Seventy percent of the AIDS patients have neurological complications. Seizures are one
of the complications and can occur at any stage. Seizures can be life-threatening and
treatment with anticonvulsants is warranted. The therapeutic dilemma occurs in this case
because of the interactions between the anticonvulsants, especially the first generation
anticonvulsants, with antiretroviral agents resulting in significant side-effects including tox-
icity.The non-availability of second-generation anticonvulsants and cost constraints further
limit the choices for the physicians. In this mini-review, we discuss the management of
AIDS related seizures with emphasis on the drug–drug interactions between anticonvul-
sants and antiretroviral agents. We will also address the future directions and the need for
prospective studies with second-generation anticonvulsants.
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INTRODUCTION
Neurological symptoms are commonly encountered in HIV
patients, which range from meningitis, encephalopathy, and neo-
plasm to seizures (1, 2). New onset seizures were reported in AIDS
patients in several studies (3–6). Holtzman and colleagues stud-
ied 100 cases of HIV patients and 18 out of 100 presented with
seizures (3). Labar and Harden described generalized convulsions
as most common seizures seen in 75% of the AIDS patients.
Labar and Harden, in 13% of the patients, also reported general-
ized convulsive status epilepticus (7). Epilepsia partialis continua
has also been reported in these HIV infected patients (8, 9).
Bartolomei and colleagues described chronic focal myoclonus in
AIDS patients (8). Ferrari et al. described HIV-associated progres-
sive multifocal leukoencephalopathy (PML) presenting as epilep-
sia partialis continua (9). Pascual-Sedano and colleagues (10)
reported partial seizures in 67% of the patients with an intracranial
lesion.
The diagnosis of seizures in HIV patients includes neuroimag-
ing, lumber puncture, and electroencephalogram (EEG). Harden
et al. showed low amplitude EEG in AIDS dementia complex
(11). Gabzuda et al. performed routine EEGs on a series of
AIDS patients. The results showed generalized slowing in 38%,
focal slowing in 19%, epileptiform activity in 6 and 37% had
unremarkable EEGs (12).
In this mini-review article, we discuss the role of anticonvul-
sants in seizure management in AIDS patients.
TREATMENT OF AIDS RELATED SEIZURES WITH ANTICONVULSANTS IN
PATIENTS ON ANTIRETROVIRAL THERAPY – BENEFITS AND PITFALLS
Treatment with anticonvulsants in AIDS related seizures is neces-
sary to prevent recurrent breakthrough seizures and to improve
the quality of life of these patients.
There are several studies, which report the concomitant use
of antiepileptic drugs (AEDs) in patients on antiretroviral therapy
(ART). Birbeck et al. discussed the evidence-based guidelines from
the International League against Epilepsy (ILAE) and the Ameri-
can Academy of Neurology (AAN) for antiepileptic drug selection
for people with HIV/AIDS. The AAN and the ILAE formed a
joint panel to evaluate the literature on concurrent usage of AEDs
and antiretroviral drugs (ARVs). From 1950 to 2010, they queried
six major databases and found 4,480 articles with potential data.
These articles were reviewed first by their titles and abstract. The
remaining 68 full articles were reviewed. Three Class III articles
comprising 434,100,550 subjects identified a new onset seizure
in 2.6–61% of HIV positive patients. In HIV patients who had
not initiated ARV therapy, three class III studies of 255,101,272
patients indicated a 6.7–52.5% occurrence of peripheral neuropa-
thy symptoms. This increased to 17–55% of HIV patients devel-
oping peripheral neuropathy symptoms after ARV initiation in
two class III studies of 173, 2762 subjects. Patients receiving riton-
avir/atazanavir may require an increase in lamotrigine to maintain
levels, by as much as another 50% of the current lamotrigine
dosage. Patients receiving valproic acid may require a reduction of
zidovudine dose to maintain serum concentration of valproic acid.
Patients may not require dosage adjustments if they are receiving
valproic acid and efavirenz, raltegravir/atazanavir and lamotrigine,
or raltegravir and midazolam.
The review of seven articles showing a correlation of enzyme-
inducing antiepileptic drugs (EI-AEDs) and decreased viral sup-
pression rates and subtherapeutic ARV levels led the panel to
caution the use of EI-AEDs in patients with ARV therapy with
protease inhibitors (PIs) or non-nucleoside reverse transcrip-
tases (NNRTIs). When EI-AEDs need to be used, monitoring is
recommended (13).
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Siddiqi et al. conducted a literature review of the diagnosis
and treatment of new onset seizures in patients with HIV. There
are many potential causes of seizures in HIV positive patients,
including infections, metabolic disturbances, medication side-
effects, drug–drug interactions, and cerebrovascular disease. The
etiology is unidentifiable in 28% of HIV positive patients. In the
case of an acute symptomatic seizure due to an identifiable cause,
AED treatment is recommended for 3–6 months with subsequent
reassessment.
For chronic management of seizures, the choice of AED must
take into consideration possible interactions with the patient’s
ARV regimen. For patients treated with PIs and NNRTIs, studies
recommend avoiding EI-AEDs, including primidone phenytoin,
phenobarbital, and carbamazepine. However, in resource-limited
settings, EI-AEDs are the most commonly used, and in some
cases, are the only available options. Carbamazepine and pheny-
toin demonstrated a reduced half-life of the NNRTI nevirapine.
While previous in vitro studies have shown valproic acid in HIV
positive patients to stimulate HIV replication, in vivo studies have
not shown this.
The authors state that when available, the recommended AEDs
are levetiracetam followed by lacosamide, gabapentin, and pre-
gabalin. All four are renally metabolized and do not interact with
any AEDs or ARVs. Levetiracetam and lacosamide can be adminis-
tered orally or intravenously, but levetiracetam has the additional
benefit of being more moderately priced and does not need to
be avoided in patients with second and third degree atrioventric-
ular block, which is the case with lacosamide. Gabapentin and
pregabalin can be administered only orally, and the costs range
from moderate to expensive. In the event of medically refractory
epilepsy, surgery may be an option for patients with focal brain
lesions. Vagal nerve stimulators can be an option in poor surgical
candidates but these require a higher level care center and greater
costs (14).
Okulicz et al. conducted a case control study of HIV patients
to determine the effect of EI-AEDs on serum antiretroviral lev-
els. The EI-AEDs phenytoin, carbamazepine, or phenobarbital
with concurrent use of a non-nucleoside reverse transcriptase
(NNRTI; efavirenz or nevirapine) or a protease inhibitor (PI;
lopinavir/ritonavir, atazanavir, or darunavir) were included. Ten
study subjects were identified from the US Military HIV Nat-
ural History Study of 5,300 current and retired military members
and beneficiaries with HIV aged at least 18 years. Patients were
included if they had been on an ARV regimen for at least 6 months,
on an EI-AED for at least 28 consecutive days during that period,
and if serum EI-AED and ARV levels suggested medication com-
pliance. Twenty-five control subjects with 30 overlap periods were
identified as individuals that were not on an EI-AED (NEI-AED)
and an ARV who met the inclusion criteria. In the study group,
there were 16 periods of combined ARV/EI-AED use, most com-
monly for an unspecified seizure disorder (N = 5 of 10), focal
epilepsy (N = 1), status epilepticus secondary to herpes simplex
virus (HSV) encephalitis (N = 1), seizures secondary to PML
(N = 1), trigeminal neuralgia (N = 1), or distal motor sensory
neuropathy (N = 1). There were no statistically significant differ-
ences in demographics, with the age at diagnosis (32 years study
group vs. 33 years control group), age at first AED/ARV overlap
(42 vs. 47 years), female gender (10 vs. 12%), CD4 count at first
AED/ARV overlap (377 vs. 397), and months of AED/ARV over-
lap (20 vs. 27). The EI-AED group had higher percentages than
controls of overlap of intervals with one or more ARV intervals
below Cmin (37.5 vs. 23.3%; p= 0.124). This analysis excluded six
below the reference range EI-AED levels in EI-AED/ARV over-
lap periods, there was a statistically significant difference when
60% of the EI-AED group AED/ARV overlaps with one or more
ARV levels below Cmin (vs. 23.3% p= 0.008). The authors con-
cluded that there was a substantial impact of EI-AEDs on ARV
drug levels (15).
In another study, Lee et al. conducted a retrospective chart
review to investigate the impact of AED use in persons with
HIV/AIDS and the in vitro effects of common AEDs on HIV repli-
cation and T cell proliferation. A search of the Southern Alberta
Clinic database from January 2001 to May 2007 yielded 1,345
HIV positive patients in active treatment, of which 169 received
AEDs. Sixty percent of these patients received AEDs for periph-
eral neuropathy, followed by 24% for seizure/epilepsy, 13% for
mood disorders, and 2% for a movement disorder. The most
commonly used AEDs were gabapentin, followed by valproate,
carbamazepine, lamotrigine, phenytoin, and topiramate. AED-
treated patients were divided into an “aviremic” group if they
had received combined ART for at least 1 month with an unde-
tectable plasma viral load before AED initiation, or “viremic” if
they had a detectable viral load or had no previous ART prior to
AED initiation. In a nested cohort of 55 aviremic patients receiving
AEDs and ART, exposure to a sodium channel blocker (pheny-
toin, carbamazepine, lamotrigine) and calcium channel blockers
(gabapentin/pregabalin) were associated after 12 months of ther-
apy with increased CD4 T cell levels (p< 0.05), and had no change
in CD8 T cell levels. The authors concluded that while patients
had received high cumulative doses of AEDs with concurrent
ART, there was a potential benefit to immune status and was
comparatively safe (16).
Liedtke et al. conducted a literature review to investigate the
interactions between AEDs and ARVs and their clinical signifi-
cance. A PubMed search from 1966 to April 2003 using individual
AED and ARV drug names with other key terms such as anti-
convulsant, antiepileptic, and antiretroviral was conducted. The
articles and scientific meeting abstracts were reviewed. Drug inter-
actions between AEDs and PIs were described by six case reports. In
patients receiving concurrent ritonavir and carbamazepine, there
was a twofold to threefold increase in carbamazepine concen-
tration resulting in toxicity. When carbamazepine and indinavir
concurrent therapy was used, there was a loss of viral suppres-
sion. Decrease in phenytoin serum concentration with nelfinavir
therapy was also reported in one patient. One patient with con-
current ritonavir and phenytoin had a 30% reduction in pheny-
toin serum concentration, while in another patient on the same
combination there was no change. Two case reports of second
generation AEDs and ARVs were included, which showed no
CYP450 involvement. Lamotrigine was decreased in a patient
receiving lamotrigine and ritonavir. A report of lamotrigine use
with lopinavir/ritonavir, lamivudine, and stavudine resulted in
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a decline in viral load after 2 months of therapy and seizure
freedom (17).
Romanelli et al. conducted a literature review of ARV and AED
use in HIV positive patients. The authors did not include the meth-
ods of this search, key terms, number of articles found, or the
review process of which articles to be included. Six epidemiologi-
cal studies including 286 cases of new onset seizures reported that
seizure etiologies were most commonly brain mass lesions (two
of six studies), opportunistic infections (two of six studies), and
idiopathic (two of six studies). In two of the studies that delineated
between the different causes of opportunistic infections, cerebral
toxoplasmosis was the most commonly reported (~30%). Six stud-
ies indicated the correlation of hypoalbuminemia increasing the
free concentrations of highly protein bound drugs. AED exam-
ples were phenytoin, carbamazepine, clonazepam, and diazepam
and ARV examples were delavirdine efavirenz, saquinavir riton-
avir, nelfinavir, lopinavir, and amprenavir. Two cases of HIV-
hypoalbuminemia reported increased free phenytoin concentra-
tions in 21 patients and increased phenytoin and valproic acid
levels, respectively. HIV hypergammaglobulinemia was noted in
four cases to predispose patients to potentially life threatening
hypersensitivity reactions. One of these reported that 14% of HIV
positive patients receiving phenytoin had hypersensitivity reac-
tions, including Stevens – Johnson syndrome. Finally, five studies
included the possible correlation of valproic acid to stimulate
in vitro HIV and cytomegalovirus (CMV) replication. However,
in one included study, six of nine patients followed for 1–13 weeks
did not show increase in viral loads. The authors advised avoidance
or cautious use of phenytoin, if necessary (18).
Romanelli and colleagues also suggested in other literature that
HIV positive individuals receiving AEDs such as VPA and pheny-
toin, commonly compete with other medications like trimetho-
prim/sulfamethoxazole (commonly used in HIV positive patients
for prophylaxis against opportunistic infections). This may lead to
increased free drug levels which in turn increases side-effects and
toxicity. VPA has also been shown to stimulate the viral repli-
cation of HIV through the reduction of intracellular levels of
glutathione and VPA has been reported to stimulate CMV repli-
cation. In patients receiving AEDs and ARVs, the authors suggest
careful monitoring of viral load, disease progression, and AED
serum levels. The authors conclude that additional controlled tri-
als of pharmacokinetic and pharmacodynamics interactions are
needed as well as in vivo studies of safety and efficacy of the use of
AEDs in HIV positive individuals (19).
CONCLUSION
The newer anticonvulsants, if available, should be used to min-
imize interactions with PIs and NNRTIs. The choices include
levetiracetam, lacosamide, gabapentin, and pregabalin, which are
renally excreted. Significant decrease in lamotrigine concentra-
tions may be seen when used with ritonavir-based regimens. Viral
load should be monitored closely if treated with valproic acid.
Enzyme-inducing antiepileptic medications should be used with
caution because of side-effects and drug–drug interactions with
antiretroviral agents.
Limited data are available regarding the use of newer anticon-
vulsants because of a lack of availability in some countries and
costs restraints in this patient subgroup. There is a need for larger
prospective trials in order to provide more data about the role of
newer anticonvulsants in HIV related seizures.
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